{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4","upperLimit":"13","value":"8.5"},{"groupId":"OG001","lowerLimit":"15","upperLimit":"15","value":"15"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"description":"Number of serious adverse events per participant based on Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0","dispersionType":"Full Range","groups":[{"description":"Neupogen 16mcg/kg x 4 days Stem cell collection Drug: high dose melphalan 140 or 200 mg/m2 stem cell infusion\n\nMelphalan: Conditioning Regimen:\n\nDrug: Melphalan: 70-100 mg/m2/dose D -2, D -1 Stem Cell Transplant: D 0\n\nNeupogen: granulocyte colony-stimulating factor (G-CSF) mobilization 16mcg/kg x 4 days\n\nStem Cell Collection: collect at least 2.5 million cluster of differentiation 34 (CD34)+ stem cells\n\nStem cell infusion: infusion of previously collected autologous stem cells","id":"OG000","title":"Melphalan"},{"description":"Neupogen 16mcg/kg x 4 days Stem Cell collection drug: high-dose melphalan 140 or 200 mg/m2 drug: Bortezomib 1.0 mg/m2/dose x 4 doses stem cell infusion\n\nBortezomib: Conditioning Regimen:\n\nDrug: Bortezomib: 1.0 mg/m2/dose D -6, D -3, D +1, D + 4 Drug: Melphalan: 70-100 mg/m2/dose D -2, D -1\n\nMelphalan: Conditioning Regimen:\n\nDrug: Melphalan: 70-100 mg/m2/dose D -2, D -1 Stem Cell Transplant: D 0\n\nNeupogen: granulocyte colony-stimulating factor (G-CSF) mobilization 16mcg/kg x 4 days\n\nStem Cell Collection: collect at least 2.5 million cluster of differentiation 34 (CD34)+ stem cells\n\nStem cell infusion: infusion of previously collected autologous stem cells","id":"OG001","title":"Melphalan + Bortezomib"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"100 days","title":"Toxicities","type":"SECONDARY","unitOfMeasure":"events per participant"}